Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Up 666.0% in August

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the target of a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling 393,700 shares, an increase of 666.0% from the July 31st total of 51,400 shares. Approximately 12.5% of the company’s shares are sold short. Based on an average daily volume of 544,900 shares, the short-interest ratio is presently 0.7 days.

Entero Therapeutics Trading Up 0.9 %

NASDAQ ENTO opened at $0.44 on Wednesday. Entero Therapeutics has a 12 month low of $0.19 and a 12 month high of $22.20. The firm has a 50-day moving average of $0.88. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.40.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.